After-Hours Jitters: Why AMAT, DLO, and ZNTL Saw Dips Despite a Bullish Market Day

What a day it was on Wall Street! We saw the benchmark S&P 500 bravely push to an all-time trading high, buoyed by July's producer price data suggesting that wholesale inflation, thankfully, held steady from the previous month. Both the Dow and Nasdaq also enjoyed solid gains, with the Dow edging up 0.1%, the S&P 500 climbing a respectable 0.6%, and the tech-heavy Nasdaq Composite advancing 0.8%. A pretty rosy picture, wouldn't you say?

But as the trading bells quieted down on Thursday, August 13, 2026, the after-hours session told a slightly different, more nuanced story for a few specific names. It's often in these quieter hours that individual company news can truly make waves, sometimes in unexpected ways, even against a strong market tide.

Take Applied Materials (AMAT), the semiconductor equipment giant, for example. You might think stellar earnings would guarantee a bump, right? Well, not always. Shares for AMAT actually slipped 2.5% after the closing bell, despite reporting fiscal third-quarter results and guidance that handily topped Wall Street's expectations. It seems investors, ever the demanding crowd, simply 'wanted more.' The company announced Q3 EPS of $3.39, a fantastic 36.7% jump year-over-year, and revenue hitting $9 billion, up a robust 23.3%. Their outlook for Q4 also looked promising, with anticipated revenue of $10.25 billion, driven by projected 2026 packaging growth soaring over 70%. And get this: U.S. sales doubled, while European revenues surged over 200%! Yet, the stock still pulled back. It just goes to show you how high expectations can truly be in this sector.

Then there's dLocal (DLO), the payment processing company. Their stock also saw a modest dip, falling 2.3% in after-hours trading. This particular slide came as their second-quarter GAAP EPS of $0.18 just barely missed the consensus estimate by a penny. The culprit, it seems, was a noticeable jump in operating expenses. Interestingly, their revenue picture was brighter, coming in at $399.7 million and comfortably beating estimates by over $32 million. Oh, and they also announced a hefty $150 million credit agreement, a piece of news that perhaps offered some reassurance amidst the earnings miss.

Finally, we turn our gaze to Zentalis Pharmaceuticals (ZNTL). This biotechnology firm experienced a more significant stumble, with its shares plummeting over 10% after the market closed. What caused such a sharp reaction? The company launched a proposed underwritten public offering of common stock and pre-funded warrants. While public offerings can sometimes be a necessary step for biotech companies seeking capital for research and development, they often dilute existing shareholder value, leading to immediate downward pressure on the stock price. Considering Zentalis's 52-week trading range, which saw it bounce between $1.21 and $6.95 as of early August, this kind of volatility isn't entirely new territory for investors in the biotechnology space. It's a reminder that even on days when the broader market is celebrating, individual companies can face their own unique challenges and investor reactions.